论文部分内容阅读
目的探讨布地奈德联合复方异丙托溴胺氧驱动雾化吸入治疗毛细支气管炎的临床疗效。方法将72例临床明确诊断为毛细支气管炎的患儿随机分为治疗组34例与对照组38例,两组在常规治疗基础上,治疗组:布地奈德混悬液0.5 mg/次及吸入复方异丙托溴胺溶液1.25 ml/次;对照组:布地奈德混悬液0.5 mg/次。观察并比较各组患儿咳嗽消失、喘憋消失、哮鸣音消失及平均住院时间。结果咳嗽消失、喘憋消失、哮鸣音消失及平均住院时间两组比较治疗组明显更短,差异均有统计学意义(P<0.05)。结论布地奈德联合复方异丙托溴胺氧驱动雾化辅助治疗毛细支气管炎临床疗效可靠,可使患儿病程缩短,治愈率提高,且副作用小,值得临床推广应用。
Objective To investigate the clinical efficacy of budesonide combined with ipratropium bromide inhalation in the treatment of bronchiolitis. Methods Seventy-two children with clinically diagnosed bronchiolitis were randomly divided into treatment group (34 cases) and control group (38 cases). On the basis of routine treatment, the two groups were treated with budesonide 0.5 mg / Compound ipratropium bromide solution 1.25 ml / time; control group: budesonide suspension 0.5 mg / time. Observation and comparison of cough disappeared in all groups, wheezing disappeared, wheeze disappeared and the average length of stay. Results Cough disappeared, wheezing disappeared, wheeze disappeared and average length of hospital stay was significantly shorter in both groups, with significant differences (P <0.05). Conclusion Budesonide combined with ipratropium bromide oxygen atomization assisted treatment of bronchiolitis clinical curative effect is reliable, can shorten the duration of children, the cure rate increased, and the side effects of small, worthy of clinical application.